Stiftingtalstraße 14 | 8010 Graz, Austria
info@cycuria.com
Contact

Home

Our Mission
At Cycuria, we are dedicated to developing novel protein-based targeted therapy to dramatically improve outcomes for patients with hematological cancers and other hard-to-treat solid cancers, offering hope where traditional treatments have fallen short.
Explore our science
Our Team
Our experienced management team brings deep expertise in hemato-oncology, protein engineering and drug development, with a focus on advancing first-in-class therapies that directly target cancer cells.
Explore our team
Your Career
Join our mission to transform blood cancer treatment with our groundbreaking approach. We offer exciting opportunities for talented scientists and drug developers to make a significant impact in the field of oncology ...
Explore your career

The Current Gap

Acute Myeloid Leukemia (AML) remains a challenging disease with poor long-term outcomes despite significant advancements in treatment.

While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival remain elusive, particularly for older or unfit patients who cannot tolerate intensive chemotherapy or stem cell transplants ...

More Details

Our Breakthrough approach

Cycuria Therapeutics is revolutionizing blood cancer treatment with its proprietary engineered biologics.

Our approach directly and specifically targets leukemic cells and their progenitor stem cells, while preserving healthy blood formation and minimizing systemic toxicity...

More Details

High incidence rate for AML,
specially in >60 yrs population

0

in every 100.000

Poor Overall survival rate
for AML patients

0 %

3-year survival rate

TEAM

Our experienced management team brings deep expertise in protein engineering, clinical hemato-oncology and early-stage drug discovery and development

Prof. Dr. Philipp J. Jost

Inventor & Co-Founder

Dr. Nisit Khandelwal

Co-Founder & CEO

Prof. Dr. Felix Wieland

Directorem. Uni Heidelberg (BZH)

Prof. Dr. Walter Nickel

Managing DirectorofBZH, Uni Heidelberg

View All

Our Blog

Latest CYCURIA News

All News

Contact Us

Cycuria Therapeutics

Center for Knowledge Transfer II (ZWT II)
Medical Science City Graz
Stiftingtalstraße 14
8010 Graz
Austria

Contact

At Cycuria, we are dedicated to developing novel protein-based targeted therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.

Copyright © 2024 / design by visualstimuli.de

Information

Contact Us

Contact
info@cycuria.com
Linkedin